ClinicalTrials.gg
CompletedNCT00077805Updated Jan 11, 2011

PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)

A Phase 4 interventional study of Enoxaparin sodium in Acute Ischemic Stroke, sponsored by Sanofi. Completed at 15 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-11.

Sponsored by Sanofi · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 480 studies in Ischemic Stroke with a site in United States — 122 open to participants now, 146 under way, 13 of them phase 3. Ischemic Stroke · United States.

Started
2003
with 8 others
Phase 4
11 of 480
3 open now
Registered
6th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is one of 9 that started in 2003, is one of 11 in phase 4, and was the 6th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

122 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

Primary objective:

  • To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.

Secondary objectives:

  • To compare the incidence of VTE between the 2 treatment groups at 30, 60, and 90 days from the time of randomization
  • To compare neurologic outcomes between the 2 treatment groups, including incidence of stroke recurrence, rate of stroke progression, and patient functional status, during the 10 ± 4 days of treatment, and after 30, 60, and 90 days from the time of randomization
  • To evaluate the safety of using enoxaparin compared to UFH for VTE prevention in patients following acute ischemic stroke
03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute ischemic stroke, any territory, with an appropriate neuroradiologic study (head CT scan or brain MRI scan) providing results consistent with non hemorrhagic stroke
  • Onset of symptoms of qualifying stroke within 48 hours prior to randomization. In patients receiving thrombolytic therapy for the acute stroke, such as tissue-type plasminogen activator (tPA), administration of study drug may not start until at least 24 hours after completion of thrombolytic therapy
  • Significant motor impairment of the leg, as indicated by a NIHSS score ≥2 on item 6
  • Inability to walk without assistance

Exclusion criteria

Exclusion criteria:

  • Females who are pregnant, breast-feeding, or of and not using medically acceptable and effective
  • Clinical evidence of VTE at screening
  • Any evidence of active bleeding on the basis of clinical judgment
  • Prior history of intracranial hemorrhage (including that at screening)
  • Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours
  • Thrombolytic therapy (e.g., tPA) or intra-arterial thrombolytic therapy within the preceding 24 hours.Thrombolytic therapy is permitted for treatment of the acute stroke but must have been completed 24 hours prior to randomization.
  • Comatose at screening (NIHSS score ≥2 on item 1a)
  • Known or suspected cerebral aneurysm or arteriovenous malformation
  • Confirmed that may pose an increased risk for bleeding or otherwise compromise follow-up or outcome assessment (e.g., lung cancer)
  • Impaired hemostasis, i.e., known or suspected coagulopathy (acquired or inherited); baseline count \<100,000/mm3; 1.5 X the laboratory ; or international normalized ratio(INR) >1.5
  • Major surgery or recent major trauma within the previous 3 months
  • Anticipated need for full-dose treatment with therapeutic levels of an anticoagulant (LMWH, UFH, oral anticoagulant), e.g., for cardiogenic source of embolism or dissection
  • Treatment with a LMWH or UFH at prophylactic dose for more than 48 hours prior to randomization(patients receiving LMWH or UFH less than 48 hours prior to randomization may be randomized)
  • Allergy to heparin or enoxaparin sodium, or known to heparin, enoxaparin, or pork products
  • History of heparin or enoxaparin induced thrombocytopenia and/or thrombosis (heparin-induced thrombocytopenia [HIT], heparin-associated thrombocytopenia [HAT], or heparin-induced thrombotic thrombocytopenia syndrome [HITTS])
  • History of hypersensitivity to iodinated contrast media and/or iodine
  • Bacterial endocarditis
  • Prosthetic heart valve
  • Known or suspected severe anemia (Hg \<10.0 g/dL)
  • Uncontrolled arterial hypertension (systolic blood pressure [BP] >180 mmHg or diastolic BP >100 mmHg) at the time of randomization or clinical hypertensive urgency
  • Any other serious diseases, including severe liver disease or renal failure [ \<30 mL/min on at least two occasions].
  • Treatment with other agents or devices within the previous 30 days, planned use of other investigational drugs or devices, or previous enrollment in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative occurrence of VTE events (deep-vein thrombosis, pulmonary embolism)

    Time frame: 10 ± 4 days following acute ischemic stroke

Secondary outcomes

  1. cumulative VTE events

    Time frame: at 30-day, 60-day and 90-day

  2. stroke recurrence, stroke progression, National Institute of Health Stroke Scale (NIHSS) scores

    Time frame: during treatment and follow-up periods

  3. Modified Rankin Scale (MRS) scores

    Time frame: at 30-day and 90-day follow-up

  4. major & minor hemorrhages

    Time frame: from the inform consent signed up to the end of the study

  5. Treatment emergent adverse events (TEAE), serious adverse events (SAE), all-cause mortality

    Time frame: from the inform consent signed up to the end of the study

07

Study locations

15 sites
  • Sanofi-Aventis
    Bridgewater, New Jersey, United States
  • Sanofi-Aventis
    North Ryde, Australia
  • Sanofi-Aventis
    Vienna, Austria
  • Sanofi-Aventis
    Sao Paulo, Brazil
  • Sanofi-Aventis
    Laval, Canada
  • Sanofi-Aventis
    Bogota, Colombia
  • Sanofi-Aventis
    Prague, Czech Republic
  • Sanofi-Aventis
    Mumbai, India
  • Sanofi-Aventis
    Natanya, Israel
  • Sanofi-Aventis
    Milan, Italy
  • Sanofi-Aventis
    Seoul, Korea, Republic of
  • Sanofi-Aventis
    Mexico, Mexico
  • Sanofi-Aventis
    Warsaw, Poland
  • Sanofi-Aventis
    Johannesburg, South Africa
  • Sanofi-Aventis
    Istanbul, Turkey
08

References and documents

Publications

  • Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O'Riordan W, Pineo GF; PREVAIL Investigators. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke. 2009 Nov;40(11):3532-40. doi: 10.1161/STROKEAHA.109.555003. Epub 2009 Aug 20. PubMed 19696423 ↗
  • Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O'Riordan W, Pineo GF; PREVAIL Investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007 Apr 21;369(9570):1347-1355. doi: 10.1016/S0140-6736(07)60633-3. PubMed 17448820 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003 and a primary completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2004
First posted
Feb 16, 2004
Start
Aug 2003
Primary completionActual
Jul 2006
Last update
Jan 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00077805
Lead sponsor
Sanofi
First posted
Feb 16, 2004
Start date
Aug 2003
Primary completion
Jul 2006
Last update
Jan 11, 2011

Study contacts

Luc Sagnard
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin sodium

Start the discussion